



Exelixis Announces Webcasts of ASCO Investor Briefings on June 5 and June 7

June 3, 2010

SOUTH SAN FRANCISCO, Calif., Jun 03, 2010 (BUSINESS WIRE) --Exelixis, Inc. (NASDAQ: EXEL) announced today that it will hold two investor briefings in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting from 6:30 p.m. to 8:00 p.m. CDT on Saturday, June 5, 2010 and 6:00 p.m. to 7:30 p.m. CDT on Monday, June 7, 2010.

The events will be available via conference call and webcast. Access numbers for the events are as follows:

Saturday June 5, 2010 - dial: 1-800-510-9691 (domestic) and +1-617-614-3453 (international); the participant passcode is: 44562547.

Monday June 7, 2010 - dial: 1-866-783-2144 (domestic) and +1-857-350-1603 (international); the participant passcode is: 72899846.

The webcasts may be accessed in the Event Calendar page under Investors at <http://www.exelixis.com>.

Participants:

- George A. Scangos, PhD, President and Chief Executive Officer
- Michael M. Morrissey, PhD, President of Research and Development
- Gisela M. Schwab, MD, Executive Vice President and Chief Medical Officer
- Ron Weitzman, Vice President, Clinical Research

Topics:

Data from ASCO, the Exelixis pipeline and general business update.

Abstracts to be presented at ASCO:

ASCO

Abstract Number	ASCO Abstract Title	Presentation Date and Time (CDT)
2006	Phase 2 study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB)	Oral Presentation: Saturday, June 5th, 5:00 p.m.
3015	A phase 1 safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.	Poster: Sunday, June 6th, 2:00 p.m. - 6:00 p.m. Discussion: Sunday, June 6th, 5:00 p.m.
3017	A phase 1b/2 study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).	Poster: Sunday, June 6th, 2:00 p.m. - 6:00 p.m. Discussion: Sunday, June 6th, 5:00 p.m.
3030	A phase 1 dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.	Poster: Sunday, June 6th, 2:00 p.m. - 6:00 p.m. Discussion: Sunday, June 6th, 5:45 p.m.

2501	A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors.	Oral Presentation: Sunday June 6th, 10:15 a.m.
-	-	-
3070	A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.	Poster: Monday, June 7th, 8:00 a.m. - 12:00 p.m.
-	-	-
3078	A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.	Poster: Monday, June 7th, 8:00 a.m. - 12:00 p.m.
-	-	-
3085	A phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma.	Poster: Monday, June 7th, 8:00 a.m. - 12:00 p.m.
-	-	-
3105	A phase 1 study of XL228, a multitargeted protein kinase inhibitor, in patients (pts) with solid tumors or multiple myeloma.	Poster: Monday, June 7th, 8:00 a.m. - 12:00 p.m.
-	-	-
5502	Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase 1 study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET.	Oral Presentation: Monday, June 7th, 10:45 a.m.
-	-	-
TPS188	An adaptive randomized discontinuation trial of XL184 (BMS-907351) in patients (pts) with advanced solid tumors	Poster: Monday, June 7th, 8:00 a.m. - 4:00 p.m.
-	-	-

To access the clinical data posters mentioned in this press release, please visit <http://www.exelixis.com>.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo. For more information, please visit the company's web site at <http://www.exelixis.com>.

Exelixis and the Exelixis logo are registered U.S. trademarks.



SOURCE: Exelixis, Inc.

Exelixis, Inc.

Investor:

Charles Butler, 650-837-7277

Vice President, Investor Relations and Corporate Communications

cbutler@exelixis.com

or

Exelixis, Inc.

Investor:

DeDe Sheel, 650-837-8231

Associate Director, Investor Relations

dsheel@exelixis.com